CardioVascular BioTherapeutics (fka CVBT)

[Beachbum3232]

Mike Flaa was a consultant and in my opinion, kept things moving during this transition from old CVBT Mgmt to Wallen's team. It is not uncommon to see consultant's leave their position once the company is ready to enter the next stage of development---usually because the company needs a more tenured Biotech professional who knows his/her way around. This is not a knock against Flaa, but just a reality. By the way I see Flaa is still on the BOD, why would he leave the company but stay on the board if things were so bad?

As for Ori Ben-Yehuda, I see on LinkedIn he's head of a clinical trial center and perhaps his role with CVBT was temporary to help guide them on getting thier trials back on track---I see CVBT has another CMO on board with a great resume.

This is all speculation but I believe "based on my experience" both were consulting and have left to allow more experienced folks come on board and take this company to the next level. Just my opinion.